Benzinga | Aug 19, 2021 07:08AM EDT

TScan Therapeutics Q2 EPS $(7.69) Down From $(6.18) YoY, Sales $2.85M

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(7.69) per share. This is a 24.43 percent decrease over losses of $(6.18) per share from the same period last year. The company reported $2.85 million in sales this quarter.